Apellis Pharmaceuticals Inc. (APLS)
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
Apellis Pharmaceuticals: Restart Of Growth Story After Empaveli's New Approval
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Caroline R. Baumal - Chief Medical Officer Cedric Francois - Co-Founder, President, CEO & Director David L.
Apellis Pharmaceuticals: The Picture Becomes Clearer
Apellis Pharmaceuticals has made pipeline progress and strengthened its balance sheet since I looked at this biopharma name earlier this year, warranting a fresh look at the stock. Recent approvals for Empaveli for two new indications and a lucrative royalty deal with Sobi enhance future revenue potential and bolster the company's balance sheet. With solid cash reserves and projected narrowing losses, Apellis is positioned for improved financial performance in the coming years.
Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.
Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
Apellis Pharmaceuticals: Have Some Patience
Apellis Pharmaceuticals is a Buy due to the significant FCF potential of SYFOVRE® and EMPAVELI®, with SYFOVRE® projected to exceed $1bn in annual sales by 2028. SYFOVRE® has shown efficacy in slowing GA progression and saw a 122% YoY sales increase in 2024, despite initial rollout issues. EMPAVELI® offers moderate sales and is in trials for additional indications, promising incremental cash flows and contributing to EBITDA positivity by 2026.
Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down
APLS stock falls as it reports weaker-than-expected first-quarter 2025 results, wherein both earnings and revenues miss estimates.
Apellis Pharmaceuticals, Inc. (APLS) Q1 2025 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q1 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Tracy Vineis – Vice President-Communications Cedric Francois – Co-Founder and Chief Executive Officer Tim Sullivan – Chief Financial Officer David Acheson – Executive Vice President-Commercial Caroline Baumal – Chief Medical Officer Conference Call Participants Jon Miller – Evercore Tazeen Ahmad – Bank of America Securities Anupam Rama – JPM Steve Seedhouse – Cantor Colleen Kusy – Baird Eliana Merle – UBS Annabel Samimy – Stifel Biren Amin – Piper Sandler Yigal Nochomovitz – Citigroup Douglas Tsao – H.C. Wainwright Lachlan Hanbury-Brown – William Blair Ryan Deschner – Raymond James Judah Frommer – Morgan Stanley Greg Harrison – Scotiabank Graig Suvannavejh – Mizuho Securities Lisa Walter – RBC Operator Hello, everyone.
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.
Apellis Pharmaceuticals, Inc. (APLS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
